Illumina, Inc. $ILMN Stock: Sigma Planning Corp Grows Stake

Sigma Planning Corp increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 91.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,980 shares of the life sciences company’s stock after acquiring an additional 3,327 shares during the quarter. Sigma Planning Corp’s holdings in Illumina were worth $1,910,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new stake in shares of Illumina in the 2nd quarter valued at about $26,000. MCF Advisors LLC lifted its position in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the period. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina during the second quarter valued at approximately $32,000. Rakuten Securities Inc. bought a new position in shares of Illumina during the second quarter valued at approximately $33,000. Finally, WealthCollab LLC boosted its stake in shares of Illumina by 51.5% during the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 103 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 3.1%

Shares of Illumina stock opened at $279.47 on Wednesday. The firm’s 50 day moving average price is $245.13 and its 200-day moving average price is $174.27. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the company earned $1.19 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research reports. Royal Bank Of Canada lifted their price objective on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Piper Sandler upped their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Stifel Nicolaus increased their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Evercore reiterated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Guggenheim lifted their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Ten research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $234.41.

Insider Activity

In other news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 2,061,850 shares of company stock worth $436,479,102 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.